Patents by Inventor Hong I. WAN

Hong I. WAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SIRP-ALPHA ANTIBODIES AND CONJUGATES
    Publication number: 20240374746
    Abstract: The present disclosure provides anti-SIRP-? polypeptide antibodies and oligonucleotide conjugates thereof. Also provided are related methods of preparation thereof and methods of use thereof, including therapeutic uses.
    Type: Application
    Filed: February 21, 2024
    Publication date: November 14, 2024
    Inventors: Min LI, Ons HARRABI, Amy CHEN, Emma Ruth SANGALANG, Tracy Chia-Chien KUO, Bang Janet SIM, Hong I. WAN, Jaume PONS
  • TRANSGLUTAMINASE-MEDIATED CONJUGATION
    Publication number: 20240287528
    Abstract: The present disclosure provides for antibody-oligonucleotide conjugates, methods of preparation thereof, and methods of use thereof. Also provided are related compounds, compositions and kits.
    Type: Application
    Filed: August 8, 2023
    Publication date: August 29, 2024
    Inventors: Jaume PONS, Hong I. WAN, Tracy Chia-Chien KUO, Curt W. BRADSHAW, Son LAM, Bang Janet SIM, Edward HyungSuk HA, Sukumar SAKAMURI
  • TRANSGLUTAMINASE-MEDIATED CONJUGATION
    Publication number: 20240191242
    Abstract: The present disclosure provides for antibody-oligonucleotide conjugates, methods of preparation thereof, and methods of use thereof. Also provided are related compounds, compositions and kits.
    Type: Application
    Filed: December 21, 2023
    Publication date: June 13, 2024
    Inventors: Jaume PONS, Hong I. WAN, Tracy Chia-Chien KUO, Curt W. BRADSHAW, Son LAM, Bang Janet SIM, Edward HyungSuk HA, Sukumar SAKAMURI
  • Transglutaminase-mediated conjugation
    Patent number: 11920136
    Abstract: The present disclosure provides for antibody-oligonucleotide conjugates, methods of preparation thereof, and methods of use thereof. Also provided are related compounds, compositions and kits.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: March 5, 2024
    Assignee: TALLAC THERAPEUTICS, INC.
    Inventors: Jaume Pons, Hong I. Wan, Tracy Chia-Chien Kuo, Curt W. Bradshaw, Son Lam, Bang Janet Sim, Edward HyungSuk Ha, Sukumar Sakamuri
  • Transglutaminase-mediated conjugation
    Patent number: 11795463
    Abstract: The present disclosure provides for antibody-oligonucleotide conjugates, methods of preparation thereof, and methods of use thereof. Also provided are related compounds, compositions and kits.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: October 24, 2023
    Assignee: TALLAC THERAPEUTICS, INC.
    Inventors: Jaume Pons, Hong I. Wan, Tracy Chia-Chien Kuo, Curt W. Bradshaw, Son Lam, Bang Janet Sim, Edward HyungSuk Ha, Sukumar Sakamuri
  • TRANSGLUTAMINASE-MEDIATED CONJUGATION
    Publication number: 20230130194
    Abstract: The present disclosure provides for antibody-oligonucleotide conjugates, methods of preparation thereof, and methods of use thereof. Also provided are related compounds, compositions and kits.
    Type: Application
    Filed: June 16, 2022
    Publication date: April 27, 2023
    Inventors: Jaume PONS, Hong I. WAN, Tracy Chia-Chien KUO, Curt W. BRADSHAW, Son LAM, Bang Janet SIM, Edward HyungSuk HA, Sukumar SAKAMURI
  • TRANSGLUTAMINASE-MEDIATED CONJUGATION
    Publication number: 20220380768
    Abstract: The present disclosure provides for antibody-oligonucleotide conjugates, methods of preparation thereof, and methods of use thereof. Also provided are related compounds, compositions and kits.
    Type: Application
    Filed: February 26, 2021
    Publication date: December 1, 2022
    Inventors: Jaume PONS, Hong I. WAN, Tracy Chia-Chien KUO, Curt W. BRADSHAW, Son LAM, Bang Janet SIM, Edward HyungSuk HA, Sukumar SAKAMURI
  • IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE
    Publication number: 20220096649
    Abstract: Provided herein is a conjugate for modulating a natural killer cell or myeloid cell, comprising a targeting moiety and an immunomodulating polynucleotide. Also provided herein is a pharmaceutical composition for modulating a natural killer cell or myeloid cell, comprising a conjugate comprising a targeting moiety and an immunomodulating polynucleotide, and a pharmaceutically acceptable excipient. Additionally provided herein are methods of their use for modulating a natural killer cell or myeloid cell and treating a proliferative disease.
    Type: Application
    Filed: October 16, 2019
    Publication date: March 31, 2022
    Inventors: Jaume PONS, Hong I. WAN, Curt W. BRADSHAW, Bang Janet SIM, Tracy Chia-Chien KUO